Global Mitochondrial Myopathy Diagnosis & Treatment Market Research Report: Information by Type (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes, Progressive External Ophthalmoplegia, Myoclonic Epilepsy with Ragged Red Fibers, Mitochondrial Neurogastrointestinal Encephalopathy Syndrome, Kearns–Sayre Syndrome (KSS), Mitochondrial DNA Depletion Syndrome, Pearson Syndrome, Leigh Syndrome, Neuropathy, Ataxia and others), Diagnostic Test (Genetic Tests, Muscle Biopsy and Biochemical Test), Deployment Models (On-Premise and Cloud-Based), Therapy (Supportive Therapy and Targeted Therapy) and Region - Forecast Till 2027
In Mitochondrial myopathy, the mitochondria are affected which leads to symptoms such as muscle weakness, muscle cramping, low immunity, poor balance, and fatigue. Mitochondrial myopathy interferes with the functioning of the muscles and might also affect the functioning of other organs. At present, there is no curative therapy for mitochondrial myopathy. As per the analysis of Market Research Future (MRFR), the global mitochondrial myopathy market is expected to exhibit an upswing and attain USD 33.6 Mn at a CAGR of 9.82% by the end of the forecast period of 2017-2020.
The growth in the global mitochondrial myopathy diagnosis & treatment market can be attributed to various factors. The spiraling rise in the incidence rate of mitochondrial myopathy is a key factor in boosting the growth of the market. As per the Australian Mitochondrial Disease Foundation (AMFD), about one in 5,000 people are likely to develop a significant mitochondrial disease. A growing number of mitochondrial myopathy cases generate massive demand for diagnosis and treatment which is well complemented by the rise in a number of screening services. Higher awareness regarding the disease has led to the development of various screening methods. Government support in the form of funding and incentives for rare genetic diseases has promoted the growth of the market. In addition, rigorous R&D activities aimed at developing therapies and treatments for mitochondrial myopathy have encouraged the growth of the market. Furthermore, a growing number of clinical trials to develop effective drugs for the disease along with the rise in a number of FDA approvals for novel drugs and therapies have proven to be beneficial for the growth of the market. On the downside, the growth of the market might be met by various bottlenecks. Lack of proper curative treatment and poor treatment options remain a major hurdle for the market growth. Due to low awareness, the diagnosis of the disease remains considerably low, especially in the developing and underdeveloped countries. Besides, the rare nature of the disease and high cost of drug development along with high investment risk remain major challenges to the growth of the market. Nevertheless, faster market uptake and low marketing cost are likely to present growth opportunities to the global mitochondrial myopathy diagnosis & treatment market.
Segmentation
The global mitochondrial myopathy diagnosis & treatment market has been segmented based on type, diagnostic tests, and therapy.
By type, the global mitochondrial myopathy diagnosis & treatment market has been segmented into neuropathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), Pearson syndrome, Leigh syndrome, ataxia, mitochondrial DNA depletion syndrome (MDS), Retinitis pigmentosa (NARP), Kearns–Sayre syndrome (KSS), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). The MELAS is the largest segment and is foreseen to capture a CAGR of 19.39% during 2017-2020.
By diagnostic test, the global mitochondrial myopathy diagnosis & treatment market has been segmented into genetic tests, muscle biopsy, and biochemical test. The genetic tests segment was the largest segment in 2016 and is projected to grow at a CAGR of 10.11% over the forecast period.
By therapy, the global mitochondrial myopathy diagnosis & treatment market has been segmented into supportive therapy and targeted therapy. The supportive therapy segment held the largest market share in 2016 and is projected to capture a CAGR of 9.82% over the forecast period.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/3950
Regional Analysis
By region, the global mitochondrial myopathy diagnosis & treatment market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas dominate the global market on account of favorable reimbursement landscape and high healthcare expenditure. The region has a general propensity to adopt new technologies earlier as compared to other regions which are an advantage for the growth of the Americas market. The Americas mitochondrial myopathy diagnosis & treatment market is anticipated to reach USD 116.7 Mn at a CAGR of 19.39% by the end of the forecast period of 2017-2020.
Europe is the second largest market for mitochondrial myopathy diagnosis & treatment spurred by high disposable income and surging awareness in the region.
The APAC mitochondrial myopathy diagnosis & treatment market is expected to reach USD 4.4 Mn at a CAGR of 9.94% by the end of the forecast period.
The MEA market is led by the Gulf nations of Saudi Arabia and UAE. The Africa region is expected to showcase moderate growth due to poor economic condition prevailing in the region and low healthcare penetration.
Competitive Landscape
The notable players in the global mitochondrial myopathy diagnosis & treatment market include Stealth Biotherapeutics, Khondrion BV, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., GeneDx, Mitobridge, Centogene AG, and Ixchel Pharma.
Industry Updates
In January 2019, Stealth Bio Therapeutics announced selling USD 86.25 of its common stock in an IPO for advancing drug candidates for the treatment of mitochondrial-based conditions. The finding will support the development of drugs to treat mitochondrial dysfunction.
Table of Content
1 Introduction
1.1 Definition 9
1.2 Scope Of Study 9
1.3 Research Objective 9
1.4 Assumptions & Limitations 10
1.4.1 Assumptions 10
1.4.2 Limitations 10
1.5 Market Structure 11
2 Research Methodology
2.1 Research Process 12
2.2 Primary Research 13
2.3 Secondary Research 13
3 Market Dynamics
3.1 Introduction 14
3.2 Drivers 15
3.2.1 Rise In Number Of Mitochondrial Myopathy Incidence Rate And Growing Number Of Screening Services. 15
3.2.2 Government Funding And Incentives For Rare Genetic Diseases 15
3.3 Restraints 16
3.3.1 Poor Treatment Options And Absence Of Curative Treatment 16
3.3.2 Lack Of Awareness And Diagnosis Of The Rare Mitochondrial Disorders 16
3.4 Opportunities 16
3.4.1 Faster Market Uptake And Low Marketing Cost 16
3.4.2 Research And Development 17
3.5 Challenges 17
3.5.1 Rare Nature Of The Disease 17
3.5.2 Poor Understanding Of Mitochondria And Genetics 17
3.5.3 Cost Of Drug Development And High Investment Risk 17
4 Market Factor Analysis
4.1 Porter’s Five Forces Analysis 19
4.1.1 Threat From A New Entrant 19
4.1.2 Bargaining Power Of Buyer 20
4.1.3 Bargaining Power Of Supplier 21
4.1.4 Threat From Substitute 21
4.1.5 Intensity Of Competitive Rivalry 21
4.2 Pipeline Analysis 23
4.2.1 Introduction 23
4.2.2 KH176 23
4.2.3 Elamipretide 24
4.2.4 RTA 408 25
4.2.5 IXC 103 26
4.2.6 NV556 26
4.3 Mega Trends 27
4.3.1 Strategies For Increasing Mitochondrial Biogenesis 27
4.3.2 Antioxidant Approaches 27
4.3.3 Targeting Mitochondrial Dynamics And Biogenesis 28
4.3.4 Mitochondrial Membrane Lipids As Therapeutic Targets 28
4.3.5 Nucleoside Replacement And Gene Therapy 28
4.3.6 Enzyme Replacement Therapy 28
4.4 Investment Opportunity Analysis 29
4.4.1 Market Size (Current And Future), Growth Rate, And Profitability 29
4.4.2 Investment Risks 29
4.4.3 Market Outlook 29
4.4.4 Competitors 30
4.4.5 Projections 30
5 Mitochondrial Myopathy Diagnosis & Treatment Market, By Type
5.1 Introduction 31
5.2 Mitochondrial Encephalomyopathy, Lactic Acidosis, And Stroke-Like Episodes (MELAS) 31
5.3 Progressive External Ophthalmoplegia (PEO) 31
5.4 Myoclonic Epilepsy With Ragged Red Fibres (MERRF) 32
5.5 Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE) 32
5.6 Kearns–Sayre Syndrome (KSS) 32
5.7 Mitochondrial DNA Depletion Syndrome (MDS) 32
5.8 Pearson Syndrome 33
5.9 Leigh Syndrome 33
5.10 Neuropathy, Ataxia, And Retinitis Pigmentosa (NARP) 33
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/mitochondrial-myopathy-diagnosis-treatment-market-3950
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Related Report:
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Mitochondrial Myopathy Diagnosis & Treatment Market Overview:In Mitochondrial myopathy, the mitochondria are affected which leads to symptoms such as muscle weakness, muscle cramping, low immunity, poor balance, and fatigue.
As per the analysis of Market Research Future (MRFR), The Global Mitochondrial Myopathy Diagnosis & Treatment Market is growing at a healthy pace and is expected to be USD 20.4 million in 2016, at a CAGR of 9.8% during the forecast period 2017-2025.The growth in the global mitochondrial myopathy diagnosis & treatment market can be attributed to various factors.
Besides, the rare nature of the disease and high cost of drug development along with high investment risk remain major challenges to the growth of the market.
Nevertheless, faster market uptake and low marketing cost are likely to present growth opportunities to the global mitochondrial myopathy diagnosis & treatment market.Mitochondrial Myopathy Diagnosis & Treatment Market SegmentationThe global mitochondrial myopathy diagnosis & treatment market has been segmented based on type, diagnostic tests, and therapy.By type, the global mitochondrial myopathy diagnosis & treatment market has been segmented into neuropathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO), Pearson syndrome, Leigh syndrome, ataxia, mitochondrial DNA depletion syndrome (MDS), Retinitis pigmentosa (NARP), Kearns–Sayre syndrome (KSS), myoclonic epilepsy with ragged red fibres (MERRF), mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE).
The MELAS is the largest segment and is foreseen to capture a CAGR of 19.39% during 2017-2020.By diagnostic test, the global mitochondrial myopathy diagnosis & treatment market has been segmented into genetic tests, muscle biopsy, and biochemical test.
The genetic tests segment was the largest segment in 2016 and is projected to grow at a CAGR of 10.11% over the forecast period.By therapy, the global mitochondrial myopathy diagnosis & treatment market has been segmented into supportive therapy and targeted therapy.
Mitochondrial Myopathy Diagnosis & Treatment Market – OverviewDNA deletions and mutations that have become rampant of late have increased the detection rates for various types of mitochondrial myopathy.
Market reports connected with the healthcare industry have been made available by Market Research Future who issues reports on other sectors that have been recently put out along with a report on this industry.
The market is anticipated to achieve revenue figures worth $ 33.6 million by the end of 2020, while growing at a projected CAGR of 9.82 % approximately in the forecast period.The advance in the screening services has improved the detection of the cases for mitochondrial myopathy, thereby increasing the potential for market growth.
Developments in the genetic tests and increased awareness from the end users are increasingly projected to reinforce market’s growth in the forecast period.Competitive AnalysisThe reform in the products and services is the central factor escalating the market's productivity and manipulating the trends that are increasing in prominence in the market.
The obtainability of a decent labor force along with resources is adding to the general market growth.
The key contenders being studied in the report are GeneDx, Khondrion BV, Ixchel Pharma, Centogene AG, Mitobridge, Reata Pharmaceuticals Inc., NeuroVive Pharmaceutical AB, Stealth Biotherapeutics and others.Detailed Regional AnalysisThe Americas region is expected to account for the major market portion owing to the presence of a promising reimbursement scenario and more expenditure on healthcare.
